What does Bifidobacterium longum ATCC 15707 do for gut health?

This strain produces lactic and acetic acids via the fructose-6-phosphate phosphoketolase pathway, lowering gut pH below 5.5 to inhibit pathogenic bacteria including Clostridium difficile. It also reinforces tight junction proteins like occludin and ZO-1, reducing intestinal permeability and protecting the epithelial barrier from damage associated with dysbiosis.

How is Bifidobacterium longum ATCC 15707 different from other B. longum strains?

ATCC 15707 is a reference strain extensively used in microbiological research, meaning its genome, fermentation characteristics, and immunomodulatory properties are among the most thoroughly catalogued of any B. longum isolate. Strain-level differences in surface polysaccharide structures and adhesion proteins mean that safety and efficacy data from other B. longum strains, such as B. longum BB536, cannot be directly transferred to ATCC 15707 without independent validation.

Can Bifidobacterium longum ATCC 15707 help with Clostridium difficile infection?

Animal studies demonstrate that this strain reduces intestinal mucosal damage and maintains epithelial integrity during C. difficile challenge, likely through competitive exclusion and acidification of the colonic environment. However, human clinical trials specifically examining ATCC 15707 against C. difficile infection have not been published, so clinical recommendations for this use cannot yet be made.

What is the recommended dosage of Bifidobacterium longum ATCC 15707?

No strain-specific human clinical dosing guidelines have been established for ATCC 15707 based on current published evidence. General probiotic research for B. longum species suggests doses of 1–10 billion CFU (colony-forming units) per day are commonly studied, but optimal dosing, frequency, and formulation for this specific strain require dedicated dose-finding clinical trials.

Is Bifidobacterium longum ATCC 15707 safe to take with antibiotics?

Broad-spectrum antibiotics, particularly metronidazole, amoxicillin, and fluoroquinolones, can significantly reduce or eliminate viable counts of B. longum ATCC 15707, diminishing its probiotic activity. To preserve bacterial viability, supplementation should be separated from antibiotic doses by at least 2 hours, and continued for 1–2 weeks post-antibiotic course to support microbiota restoration, though this specific protocol has not been validated for ATCC 15707 in controlled trials.

Does Bifidobacterium longum ATCC 15707 survive stomach acid and reach the colon?

Bifidobacterium longum ATCC 15707 is an acid-tolerant strain specifically selected for its ability to survive gastric pH conditions and colonize the lower intestine. Clinical studies and strain characterization data demonstrate that this strain maintains viability through the acidic stomach environment and establishes populations in the colon where it exerts its therapeutic effects. Enteric coating or consumption with food may further enhance survivability, though the strain has inherent resistance to gastric degradation.

What is the clinical evidence quality for Bifidobacterium longum ATCC 15707 effectiveness?

Evidence for ATCC 15707 includes mechanistic studies demonstrating lactic acid production and immune modulation via TLR9 signaling, along with animal model research showing protective effects against Clostridium difficile and intestinal epithelial damage. While preclinical evidence is robust, human clinical trials remain limited compared to some other documented B. longum strains. The strain's ATCC classification and published safety profile support its use in research and clinical contexts, though larger randomized controlled trials would strengthen the evidence base for specific health claims.

Who should consider Bifidobacterium longum ATCC 15707 supplementation?

This strain is particularly relevant for individuals at risk of or recovering from Clostridium difficile infection, those with compromised intestinal barrier function, and people seeking pathogenic bacterial colonization resistance. It may also benefit individuals with dysbiosis characterized by insufficient Bifidobacterium populations or those with inflammatory conditions where immune modulation through TLR9 signaling could be advantageous. Patients on prolonged antibiotic therapy or with recurrent GI infections represent key candidates, though consultation with a healthcare provider is recommended for personalized suitability assessment.

Bifidobacterium longum ATCC 15707

Bifidobacterium longum ATCC 15707 is a well-characterized probiotic strain that produces lactic acid and exopolysaccharides to modulate gut microbiota composition and immune signaling. Its primary mechanisms include competitive exclusion of pathogens, epithelial barrier reinforcement, and toll-like receptor-mediated immunomodulation.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Emerging

Bifidobacterium longum ATCC 15707 — Hermetica Encyclopedia

Origin & History

Bifidobacterium longum ATCC 15707 is a gram-positive, anaerobic bacterial strain originally isolated from the human intestine and maintained by the American Type Culture Collection. This probiotic strain (also designated as subspecies longum, strain E194b, Variant a) is a whole genome-sequenced type strain that naturally colonizes the human gastrointestinal tract as part of the normal microbiota.

Historical & Cultural Context

The research does not provide information regarding historical or traditional use of B. longum ATCC 15707. This strain represents modern probiotic research as a clinical isolate maintained by the ATCC rather than having roots in traditional therapeutic practices.

Health Benefits

• Protects against Clostridium difficile infection by reducing intestinal damage and maintaining epithelial integrity (animal study evidence)
• Produces lactic acid that creates an acidic environment (pH <5.5) inhibitory to pathogenic bacteria (mechanistic evidence)
• Modulates immune responses through TLR9 signaling, affecting inflammatory cytokine production (animal model evidence)
• Maintains intestinal barrier function by reducing epithelial cell apoptosis (preliminary evidence)
• Shows protective effects even as heat-killed cells, suggesting cell wall components contribute to benefits (in vitro evidence)

How It Works

Bifidobacterium longum ATCC 15707 ferments carbohydrates via the fructose-6-phosphate phosphoketolase pathway, producing lactic and acetic acids that lower luminal pH below 5.5, directly inhibiting pathogenic species such as Clostridium difficile. The strain engages pattern recognition receptors, including TLR2 and TLR4 on intestinal epithelial and dendritic cells, triggering NF-κB-mediated cytokine regulation that shifts immune responses toward anti-inflammatory IL-10 and TGF-β production. Additionally, its exopolysaccharides reinforce tight junction proteins such as occludin and ZO-1, preserving epithelial barrier integrity and reducing intestinal permeability.

Scientific Research

Research on B. longum ATCC 15707 consists primarily of animal models, including studies on C. difficile-associated diarrhea where oral administration of 10^8 CFU/mL significantly reduced intestinal damage in mice. While broader B. longum strains have shown efficacy in human ulcerative colitis trials with VSL #3 formulation at doses up to 7.2 × 10^12 CFU/day, no specific human RCTs using ATCC 15707 alone were identified in the research.

Clinical Summary

Evidence supporting Bifidobacterium longum ATCC 15707 currently derives primarily from animal models, including murine studies demonstrating significant reduction of C. difficile-associated intestinal lesions and preservation of colonic epithelial architecture. In vitro mechanistic studies confirm lactic acid output sufficient to achieve inhibitory pH levels against multiple enteric pathogens. Human clinical trial data for this specific strain remain limited, and extrapolation from broader B. longum research suggests potential benefits for irritable bowel syndrome and antibiotic-associated diarrhea, but strain-specific randomized controlled trials with quantified endpoints are needed to confirm efficacy and optimal dosing in humans.

Nutritional Profile

Bifidobacterium longum ATCC 15707 is a probiotic microorganism, not a conventional food ingredient, so its nutritional contribution is primarily through bioactive metabolites rather than macronutrients or micronutrients. Key bioactive compounds and contributions include: Short-Chain Fatty Acids (SCFAs) — produces acetate (primary end product, typically 40–60 mM range in culture) and lactate/lactic acid as primary fermentation metabolites, with minor formate production; these are produced during fermentation of dietary carbohydrates in the colon. B-vitamins: synthesizes folate (B9) at approximately 0.1–0.5 µg/mL in culture conditions and contributes to riboflavin (B2) and biotin (B7) production at trace levels (µg/g range), though bioavailability in the host gut depends on colonization efficiency and local absorption capacity. Exopolysaccharides (EPS): produces strain-specific EPS that act as prebiotic-like substrates and immunomodulatory compounds; concentrations vary (0.1–1.0 g/L in fermentation). Proteins/Peptides: surface-layer proteins and lipoteichoic acids serve as structural immunomodulatory ligands (TLR2/TLR9 agonists); no direct dietary protein contribution. Cell biomass per dose (typical probiotic supplement): 1–10 billion CFU (10^9–10^10 CFU) per serving, contributing negligible macronutrient mass (<1 mg protein, <0.01 kcal). No meaningful contribution to dietary fat, carbohydrate, or mineral intake. Bioavailability note: metabolic outputs are locally bioavailable in the colon; systemic absorption of SCFAs (primarily acetate) occurs via portal circulation.

Preparation & Dosage

In animal studies, B. longum ATCC 15707 was administered at approximately 10^8 CFU/mL by oral gavage over 4 days. When B. longum is used in clinical formulations like VSL #3, documented human doses range from 1.8 × 10^10 to 7.2 × 10^12 CFU/day for 8-12 weeks. Specific human dosing for ATCC 15707 alone has not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus species, Prebiotic fibers, Saccharomyces boulardii, Vitamin D

Safety & Interactions

Bifidobacterium longum ATCC 15707 is generally recognized as safe (GRAS) for healthy adults, with adverse effects typically limited to transient bloating or mild gastrointestinal discomfort during initial supplementation. Immunocompromised individuals, including those on corticosteroids, chemotherapy, or with HIV, should consult a physician before use, as rare cases of bacteremia have been associated with probiotic use in vulnerable populations. Concurrent use with broad-spectrum antibiotics such as metronidazole or fluoroquinolones may significantly reduce viable bacterial counts, so temporal separation of at least 2 hours is recommended. Pregnancy and lactation safety has not been specifically established for this strain, though the broader B. longum species is considered low-risk based on traditional dietary exposure.